Trial Profile
A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Vandetanib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 30 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Oct 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 18 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.